167 related articles for article (PubMed ID: 11490833)
1. Serum levels of interleukin-2 and tumor necrosis factor-alpha correlate to tumor progression in gastric cancer.
Forones NM; Mandowsky SV; Lourenço LG
Hepatogastroenterology; 2001; 48(40):1199-201. PubMed ID: 11490833
[TBL] [Abstract][Full Text] [Related]
2. The use of tumor markers as predictors of prognosis in gastric cancer.
Mihmanli M; Dilege E; Demir U; Coskun H; Eroglu T; Uysalol MD
Hepatogastroenterology; 2004; 51(59):1544-7. PubMed ID: 15362797
[TBL] [Abstract][Full Text] [Related]
3. Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma.
Tanaka K; Miki C; Wakuda R; Kobayashi M; Tonouchi H; Kusunoki M
Scand J Gastroenterol; 2004 Aug; 39(8):754-60. PubMed ID: 15513361
[TBL] [Abstract][Full Text] [Related]
4. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
Lai IR; Lee WJ; Huang MT; Lin HH
Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer.
Kodera Y; Yamamura Y; Torii A; Uesaka K; Hirai T; Yasui K; Morimoto T; Kato T; Kito T
Am J Gastroenterol; 1996 Jan; 91(1):49-53. PubMed ID: 8561143
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer.
Kim HJ; Lee KW; Kim YJ; Oh DY; Kim JH; Im SA; Lee JS
Acta Oncol; 2009; 48(3):385-90. PubMed ID: 18855156
[TBL] [Abstract][Full Text] [Related]
7. Serum interleukin-6 levels reflect disease status of gastric cancer.
Wu CW; Wang SR; Chao MF; Wu TC; Lui WY; P'eng FK; Chi CW
Am J Gastroenterol; 1996 Jul; 91(7):1417-22. PubMed ID: 8678006
[TBL] [Abstract][Full Text] [Related]
8. Application of C12 multi-tumor marker protein chip in the diagnosis of gastrointestinal cancer: results of 329 surgical patients and suggestions for improvement.
Yang XQ; Yan L; Chen C; Hou JX; Li Y
Hepatogastroenterology; 2009; 56(94-95):1388-94. PubMed ID: 19950797
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of preoperative CEA and CA 19-9 levels in resectable gastric cancer.
Dilege E; Mihmanli M; Demir U; Ozer K; Bostanci O; Kaya C; Aksakal O; Sakiz D
Hepatogastroenterology; 2010; 57(99-100):674-7. PubMed ID: 20698248
[TBL] [Abstract][Full Text] [Related]
10. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
Chen CC; Yang SH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC
J Surg Res; 2005 Apr; 124(2):169-74. PubMed ID: 15820244
[TBL] [Abstract][Full Text] [Related]
11. [CEA, CA-19-9 and il-8, sTNFRII and sil-2R in persons at high risk of colorectal cancer].
Grotowski M; Wojtuń S
Pol Merkur Lekarski; 2003 Apr; 14(82):327-30. PubMed ID: 12868194
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer.
Rich T; Innominato PF; Boerner J; Mormont MC; Iacobelli S; Baron B; Jasmin C; Lévi F
Clin Cancer Res; 2005 Mar; 11(5):1757-64. PubMed ID: 15755997
[TBL] [Abstract][Full Text] [Related]
13. Serum tumor necrosis factor in patients with gastric cancer.
Wu CW; Chi CW; Hsieh MC; Chao MF; Lui WY; P'Eng FK
Anticancer Res; 1998; 18(3A):1597-9. PubMed ID: 9673376
[TBL] [Abstract][Full Text] [Related]
14. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
15. Pre-operative serum levels of sialyl Tn antigen predict liver metastasis and poor prognosis in patients with gastric cancer.
Nakagoe T; Sawai T; Tsuji T; Jibiki M; Nanashima A; Yamaguchi H; Yasutake T; Ayabe H; Arisawa K; Ishikawa H
Eur J Surg Oncol; 2001 Dec; 27(8):731-9. PubMed ID: 11735169
[TBL] [Abstract][Full Text] [Related]
16. [Preoperative serum levels of CEA and CA19-9 in patients with gastric cancer].
Roviello F; Garosi L; Marrelli D; De Stefano A; Udhris C; Messano A; Pinto E
Minerva Chir; 1996 Mar; 51(3):133-9. PubMed ID: 8684652
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer.
Ucar E; Semerci E; Ustun H; Yetim T; Huzmeli C; Gullu M
Adv Ther; 2008 Oct; 25(10):1075-84. PubMed ID: 18821070
[TBL] [Abstract][Full Text] [Related]
18. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
[TBL] [Abstract][Full Text] [Related]
19. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
Ozkan H; Kaya M; Cengiz A
Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer.
Gasser M; Gerstlauer C; Grimm M; Bueter M; Lebedeva T; Lutz J; Maeder U; Ribas C; Ribas C; Nichiporuk E; Thalheimer A; Heemann U; Thiede A; Meyer D; Waaga-Gasser AM
Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
